Premium
Enprostil inhibits post‐prandial gastrin release: a dose—response study
Author(s) -
LANZONMILLER S.,
ALLISON M. C.,
POUNDER R. E.,
BALL S.,
HAMILTON M. R.,
CHRONOS N. A. F.
Publication year - 1988
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1988.tb00703.x
Subject(s) - post prandial , gastrin , medicine , placebo , endocrinology , plasma levels , plasma concentration , diabetes mellitus , secretion , alternative medicine , pathology
SUMMARY In a double‐blind placebo‐controlled study in nine healthy volunteers, the effects of single doses of oral enprostil (8.75, 17.5, 35 and 70 μg), taken before a standard breakfast, were assessed on the post‐prandial release of gastrin into the plasma. All doses of enprostil caused a significant dose‐related decrease in median post‐prandial plasma gastrin concentration (range from — 29 to — 44%). In the same subjects, two doses of 25 mg indomethacin caused a significant (38%) increase in median post‐prandial plasma gastrin concentration.